This approach was pioneered by the ability of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) to selectively kill BRCA-mutant cells [15, 16], and these drugs are now yielding major benefits for patients with HRD tumours [17–20]. This evidence concerns the gene PARP1 and neoplasm.